Glucose-regulated protein 78 is an antiviral against hepatitis A virus replication

XIA JIANG1, TATSUO KANDA1, YUKI HAGA1, REINA SASAKI1, MASATO NAKAMURA1, SHUANG WU1, SHINGO NAKAMOTO2, HIROSHI SHIRASAWA2, HIROAKI OKAMOTO3 and OSAMU YOKOSUKA1

Departments of 1Gastroenterology and Nephrology and 2Molecular Virology, Graduate School of Medicine, Chiba University, Chiba 260-8670; 3Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke, Tochigi 329-0498, Japan

Received February 2, 2016; Accepted February 17, 2017

DOI: 10.3892/etm.2017.4407

Abstract. Infection with hepatitis A virus (HAV) is a major cause of acute hepatitis globally and it is important to identify the mechanisms of HAV replication. Glucose-regulated protein 78 (GRP78) is an endoplasmic reticulum (ER) chaperone and serves a role in unfolded protein response pathways. Previous studies have demonstrated that GRP78 functions as an endogenous antiviral factor. In the present study, two loss-of-function studies using GRP78 were completed to elucidate the role of GRP78 in HAV infection. HAV replication was observed to be enhanced by deficient GRP78 although GRP78-deficiency also led to lower expression of ER stress molecules downstream of GRP78. Therefore, GRP78 appears to be a potential novel defensive molecule against HAV in hepatocytes.

Introduction

The hepatitis A virus (HAV) belongs to the Hepatovirus genus of the Picornaviridae family. HAV is a positive single-stranded RNA virus ~7.6 kb in length. Although effective prophylactic vaccines have been available for a number of years, HAV infection remains a major cause of acute hepatitis globally. HAV infection may lead to acute liver failure, resulting in certain patients requiring a liver transplant (1,2). Therefore, it is important to improve the understanding of the pathogenesis of hepatitis A.

Glucose-regulated protein 78 (GRP78) is an endoplasmic reticulum (ER) chaperone and serves a role in signaling unfolded protein response (UPR). Viral infection induces ER stress and interferon responses, and certain viruses interact with GRP78 (3). GRP78 also acts as a master control interacting with the following three mediators: PKR-like ER kinase (PERK), activating transcription factor (ATF)-6 and the ER transmembrane protein kinase/endoribonuclease (IRE1) (3). Downstream of IRE1 is X-box-binding protein 1 (XBPI) and C/EBP homologous proteins, while downstream of PERK, growth arrest and DNA damage gene 34 exist. They function as effector molecules activated by ER stress (4). A previous study (5) demonstrated that GRP78 functions as an endogenous anti-hepatitis B virus (HBV) factor, which works through the interferon-β-mediated signaling pathway in hepatocytes. Ma et al (5) reported that suppression of GRP78 increases HBV replication and HBV antigen expression. Treatment with thapsigargin, an unfolded response inducer, may decrease hepatitis C virus replication (6). However, the role of GRP78 in HAV infection is not well known. The present study investigated the association between HAV replication and ER stress marker GRP78 expression.

Materials and methods

Cell lines and HAV strain. Huh7 human hepatoma cells, kindly provided by Professor R. Bartenschlager (University of Mainz, Mainz, Germany), were grown in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, Merck KGaG, Darmstadt, Germany) supplemented with 10% fetal calf serum (FCS; Sigma-Aldrich; Merck KGaG) at 5% CO2 and 37°C (7). The HAV HA-11-1299 genotype IIIA strain was used for HAV infection in all experiments (8). This HAV cell culture-adapted strain was established in Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke, Tochigi, Japan (8).

Infection with HAV in Huh7 and its derived cells. HAV infection was performed as previously described (8). Briefly, cells were plated for 24 h prior to infection at a density of 1x104 cells/well in 6-well plates (AGC Techno Glass, Shizuka, Japan). The cells were washed twice with phosphate-buffered saline (PBS) and infected with HAV HA-11-1299 genotype IIIA at a multiplicity of infection (MOI) of 0.1 in DMEM supplemented with 2% FCS (8). At 24 h after infection, the cells were washed three times with
The membranes were probed with primary antibodies against GRP78 (#3177), ATF4 (#11815; all 1:1,000; all from Cell Signaling Technology, Danvers, MA, USA), ATF6 (sc-166659), XBP1 (sc-80154) or GAPDH (sc-25778; all 1:1,000; all from Santa Cruz Biotechnology, Inc.) at 4˚C for 16 h. Anti-mouse IgG HRP-linked antibody (NA931; dilution, 1:7,000; GE Healthcare Life Sciences, Chalfont, UK) or anti-rabbit IgG HRP-linked antibody (#7074; dilution, 1:3,500; Cell Signaling Technology) were used as secondary antibodies, incubated at room temperature for 1 h. Proteins were visualized using an enhanced chemiluminescent ECL Western blot substrate (Amersham ECL Prime Western Blotting Detection Reagent; GE Healthcare Life Sciences, Chalfont, UK) and scanned with an image analyzer LAS-4000 (Fujifilm Corporation, Tokyo, Japan) and Image Gauge (version 3.1; Fujifilm) (4).

Statistical analysis. Data are expressed as the mean ± standard deviation, unless otherwise stated. Statistical analyses were performed using Student’s t-test. P<0.05 was considered to represent a statistically significant difference.

Results and Discussion
Effects of the knockdown of GRP78 on HAV replication. The effects of the knockdown of GRP78 on HAV replication were investigated. si-GRP78 and si-C were respectively transfected into HuH7 cells. These siRNAs were validated as in previous studies (4,11). At 24 h after transfection, cells were infected with HAV HA-11-1299 genotype IIIA at a MOI of 0.1. HAV RNA levels were measured 96 h after infection using RT-qPCR. This confirmed that HAV replication was significantly inhibited when GRP78 was knocked down.

Figure 1. Effects of GRP78 knockdown on HAV replication in HuH7 cells. Cells were transfected with si-GRP78 or si-C 1 day prior to HAV infection. Cellular RNA was extracted and subjected to reverse transcription-quantitative polymerase chain reaction 96 h after HAV HA-11-1299 genotype IIIA strain infection at a multiplicity of infection of 0.1. Data are expressed as the mean ± standard deviation. *P<0.05 vs. si-C-transfected controls using Student’s t-test. All experiments were performed in triplicate. GRP78, glucose regulated protein 78; HAV, hepatitis A virus; si-GRP78, siRNA against GRP78; si-C, control siRNA.
significantly increased 8.7-fold in Huh7 cells transfected with si-GRP78, compared with those with si-C (Fig. 1).

**Effects of knockout of GRP78 on HAV replication.** To confirm the effects of GRP78 on HAV replication, GRP78 was knocked out using a CRISPR/Cas9 system in Huh7 cells (12-14), and whether HAV replication was increased by the knockout of GRP78 was examined. As observed in Fig. 2A, Huh7-knockout clones exhibited significant enhancement of HAV replication compared with the parent Huh7 cells. As presented in Fig. 2B, GRP78-knockout Huh7 cells also had lower expression levels of ATF6, ATF4 and XBP1, which are located in ER stress pathways downstream of GRP78 and are of particular interest. Thus, the knockout of GRP78 appears to lead to reduced expression of other ER stress molecules such as ATF4, ATF6 and XBP1.

In the present study, HAV replication was increased by the knockdown or complete knockout of GRP78. A previous study (5) demonstrated that GRP78, an ER stress marker, is one of the intracellular antiviral factors against HBV. The silencing of GRP78 has also been shown to inhibit Dengue viral entry and multiplication in HepG2 cells (15).

A study involving GRP78-knockout mice (16) indicated that the level of XBP1s was reduced in GRP78-deficient mouse embryonic fibroblasts with impaired adipogenesis. In PERK-knockout mice (17) and XBP1-knockout mice (18), dysregulation of GRP78 occurred during the early ablation of these genes. In the present study in addition to a previous study (11), GRP78-deficiency in hepatic cells leads to the downregulation of ATF4, ATF6 and XBP1.

Recent genome-editing technology makes it possible for Cas9 nucleases to be directed by short RNAs to facilitate homology-directed repair with minimal mutagenic activity (13,14). Targeting HBV covalently closed circular DNA with CRISPR/Cas9 may efficiently inhibit viral replication (19,20). In general, there are two forms of antiviral agents, namely direct-acting antivirals and host-targeting agents (21). GRP78 is potentially a candidate host-targeting agent.

HAV infection may lead to the swelling of the perinuclear space and the ER (22). HAV interacts with the host cell and modifies the ER-Golgi intermediate compartment structure (23). HAV appears to induce ER stress and, confronted with the UPR, may lead to the type of apoptotic cell death observed with other picornaviruses (24). Coxackievirus A9 infection of permissive cells requires GRP78 and major histocompatibility complex class I molecules, which are essential for virus internalization (25). It has been reported that the expression of GRP78 is activated by an enterovirus 71-dependent mechanism and that enterovirus 71 infection induces ER stress, but modifies the outcome to assist viral replication (26).

The results of the present study support the recent study (27) and indicate that GRP78 is an attractive target for controlling HAV infection. In conclusion, GRP78 may be an intracellular anti-HAV factor, and is a novel line of defense against HAV in hepatocytes.

**Acknowledgements**

The authors thank Professor Ralf Bartenschlager for providing the Huh7 cells. The present study was supported by grants from the Ministry of Health, Labour and Welfare of Japan. This research was partially supported by the Research Program on Hepatitis from the Japan Agency for Medical Research and Development (AMED).
References

1. Collier MG, Khudaykov YE, Selvage D, Adams-Cameron M, Epstein E, Cronquist A, Jervis RH, Lamba K, Kimura AC, Sowadsky R, et al: Outbreak of hepatitis A in the USA associated with frozen pomegranate arils imported from Turkey: An epidemiological case study. Lancet Infect Dis 14: 976-981, 2014.

2. Miyamura T, Ishii K, Kanda T, Tawada A, Sekimoto T, Wu S, Nakamoto S, Arai M, Fujiwara K, Imazeki F, et al: Possible widespread presence of hepatitis A virus subgenotype IIIA in Japan: Recent trend of hepatitis A causing acute liver failure. Hepatol Res 42: 248-253, 2012.

3. He B: Viruses, endoplasmic reticulum stress, and interferon responses. Cell Death Differ 13: 393-403, 2006.

4. Kanda T, Jiang X, Nakamura M, Haga Y, Sasaki R, Wu S, Nakamoto S, Imazeki F and Yokosuka O: Overexpression of the androgen receptor in human hepatoma cells and its effect on fatty acid metabolism. Oncol Lett (In press).

5. Ma Y, Yu J, Chan HL, Chen YC, Wang H, Chen Y, Chan CY, Go MY, Tsiu SN, Ngai SM, et al: Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus. Mol Cell Proteomics 8: 2582-2594, 2009.

6. Nakagawa M, Sakamoto N, Tanabe Y, Koyama T, Itsui Y, Takeda Y, Chen CH, Kakinuma S, Oooka S, Maekawa S, et al: Suppression of hepatitis C virus replication by cycloporsin A is mediated by blockade of cyclophilins. Gastroenterology 129: 1031-1041, 2005.

7. Kanda T, Yokosuka O, Imazeki F, Tanaka M, Shino Y, Shimada H, Tomonaga T, Nomura F, Nagao K, Ochiai T, et al: Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: Ribavirin induces mutagenesis in HCV RNA. J Viral Hepat 11: 479-487, 2004.

8. Kanda T, Sasaki R, Nakamoto S, Haga Y, Nakamura M, Shirasawa H, Okamoto H and Yokosuka O: The sirtuin inhibitor sirtinol inhibits hepatitis A virus (HAV) replication by inhibiting HAV internal ribosomal entry site activity. Biochem Biophys Res Commun 466: 567-571, 2015.

9. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408, 2001.

10. Wu S, Kanda T, Imazeki F, Nakamoto S, Tanaka T, Arai M, Roger T, Shirasawa H, Nomura F and Yokosuka O: Hepatitis B virus antigen physically associates with receptor-interacting serine/threonine protein kinase 2 and regulates IL-6 gene expression. J Infect Dis 206: 415-420, 2012.

11. Jiang X, Kanda T, Nakamoto S, Miyamura T, Wu S and Yokosuka O: Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. Exp Cell Res 325: 326-336, 2014.

12. Malì P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE and Church GM: RNA-guided human genome engineering via Cas9. Science 339: 823-826, 2013.

13. Cong L, Ran FA, Cox D, Lin S, Barnett R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA and Zhang F: Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819-823, 2013.

14. Ran FA, Hsu PD, Lin CY, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y and Zhang F: Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154: 1380-1389, 2013.

15. Alhoot MA, Wang SM and Sekaran SD: RNA interference mediated inhibition of dengue virus multiplication and entry in HepG2 cells. PLoS One 7: e34060, 2012.

16. Zhu G, Ye R, Jung DY, Barron E, Friedline RH, Benoit VM, Hinton DR, Kim JK and Lee AS: GRP78 plays an essential role in adipogenesis and postnatal growth in mice. FASEB J 27: 955-964, 2013.

17. Feng D, Wei J, Gupta S, McGrath BC and Cavender DR: Acute ablation of PERK results in ER dysfunctions followed by reduced insulin secretion and cell proliferation. BMC Cell Biol 10: 61, 2009.

18. Jurczak MJ, Lee AH, Jornayvaz FR, Lee HY, Birkenfeld AL, Guigni BA, Kahn M, Samuel VT, Glimcher LH and Shulman GI: Dissociation of inositol-requiring enzyme (IRE1α)-mediated c-Jun N-terminal kinase activation from hepatitis B virus resistance in conditional X-box-binding protein-1 (XBP1) knock-out mice. J Biol Chem 287: 2558-2567, 2012.

19. Dong C, Qu L, Wang H, Wei L, Dong Y and Xiong S: Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res 118: 110-117, 2015.

20. Wang J, Xu ZW, Liu S, Zhang RY, Ding SL, Xie XM, Long L, Chen XM, Zhuang H and Lu FM: Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World J Gastroenterol 21: 9554-9565, 2015.

21. Kanda T, Nakamoto S, Wu S, Nakamura M, Jiang X, Haga Y, Sasaki R and Yokosuka O: Direct-acting antivirals and host-targeting agents against the hepatitis A virus. J Clin Transl Hepatol 3: 205-210, 2015.

22. Klinger MH, Kämmerer R, Horne B and Gauss-Müller V: Perinuclear accumulation of hepatitis A virus proteins, RNA and particles and ultrastructural alterations in infected cells. Arch Virol 146: 2291-2307, 2001.

23. Seggewiß N, Kruse HV, Weilandt R, Domsgen E, Dotzauer A and Paulmann D: Cellular localization and effects of ectopically expressed hepatitis A virus proteins 2B, 2C, 3A and their intermediates 2BC, 3AB and 3ABC. Arch Virol 161: 851-865, 2016.

24. Zhu G, Zheng Y, Zhang L, Shi Y, Li W, Liu Z, Peng B, Yin J, Liu W and He X: Coxsackievirus A16 infection triggers apoptosis in RD cells by inducing ER stress. Biochem Biophys Res Commun 441: 856-861, 2015.

25. Triantafilou K, Fradelizi D, Wilson K and Triantafilou M: GRP78, a coreceptor for coxsackievirus A9, interacts with major histocompatibility complex class I molecules which mediate virus internalization. J Virol 76 633-643, 2002.

26. Jiang JR, Lau KS, Tang WF, Wu MS and Horng JT: Endoplasmic reticulum stress is induced and modulated by enterovirus 71. Cell Microbiol 12: 796-813, 2010.

27. Nwe Win N, Kanda T, Nakamura M, Nakamoto S, Okamoto H, Yokosuka O and Shirasawa H: Free fatty acids or high-concentration glucose enhances hepatitis A virus replication in association with a reduction in glucose-regulated protein 78 expression. Biochem Biophys Res Commun 483: 694-699, 2017.